China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager Tao Weikang has resigned, citing personal reasons, effective immediately. According to Healthcare Executive, Tao has joined Qilu Pharmaceutical Co., Ltd, to serve as the Shandong-based company’s vice-president and global novel drug research and development (R&D) general manager.
New Role at Qilu Pharma
Mr. Tao will become an important member of Qilu Pharma’s global R&D system management team. In his new role, he will lead the R&D of Qilu’s global innovative drugs, formulate and implement the company’s innovative drug R&D strategy, and participate in the planning and execution of the company’s overall R&D initiatives.
Background and Experience
Before joining Qilu Pharma, Mr. Tao served as deputy general manager and R&D center chief executive officer (CEO) at Hengrui Medicine, where he was involved in the development of programmed-death 1 (PD-1) products. Prior to that, he spent over 10 years at Merck Sharp & Dohme (MSD), where he held positions as senior researcher and department head, focusing on new drug development.
Future Outlook
The appointment of Mr. Tao underscores Qilu Pharma’s commitment to strengthening its global R&D capabilities. His extensive experience in drug development, particularly in the area of innovative therapies, is expected to drive Qilu Pharma’s efforts to advance its pipeline of novel drugs.-Fineline Info & Tech
